Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme (Review)

Oncology Reports

Volumn 37, Issue 2, 2017, Pages 657-670

  Gang, Wang ^a   Wang, Jun Jie ^a,b   Fu, Xing Li ^a   Rui, Guang ^a   Tony To, Shing Shun ^c  

^a JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Glioblastoma multiforme; Glucose metabolism; HIF 1 ; Mitochondria; Oncogenes; Signaling pathways

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHJROMEN 6 YL)METHYL] N PHENYLBENZENE SULFONAMIDE; ANTINEOPLASTIC AGENT; CELASTROL; CPG OLIGODEOXYNUCLEOTIDE; DICHLOROACETIC ACID; DISUFENTON SODIUM; ECHINOMYCIN; ER 400583 00; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMIQUIMOD; MICRORNA; MICRORNA 215; MICRORNA 584 3P; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; NATURAL PRODUCT; NSC 134754; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; REACTIVE OXYGEN METABOLITE; RESVERATROL; SMALL INTERFERING RNA; STAT3 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CELL LINE; CANCER GRADING; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MITOCHONDRION; NONHUMAN; ONCOGENE; ONCOGENE CYR61; ONCOGENE IGFBP; ONCOGENE IGFBP10; ONCOGENE IGFBP6; ONCOGENE IRE1; ONCOGENE WISP1; ONCOGENE WISP2; OXIDATIVE PHOSPHORYLATION; PRACTICE GUIDELINE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; U251 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR TARGETED THERAPY;

EID: 85011807522     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5309     Document Type: Review

References (132)

1. Soøndergaard KL, Hilton DA, Penney M, Ollerenshaw M and Demaine AG: Expression of hypoxia-inducible factor 1α in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 28: 210-217, 2002.
2. Solaini G, Baracca A, Lenaz G and Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 1797: 1171-1177, 2010.
3. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
4. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH and Gassmann M: Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 15: 1312-1314, 2001.
5. Huang LE, Gu J, Schau M and Bunn HF: Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
6. Salceda S and Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
7. Majmundar AJ, Wong WJ and Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309, 2010.
8. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197, 2006.
9. Rankin EB and Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685, 2008.
10. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000.
11. Wang G, Wang J, Zhao H, Wang J and Tony To SS: The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy. Arch Biochem Biophys 580: 84-92, 2015.
12. Li J, Zhu S, Tong J, Hao H, Yang J, Liu Z and Wang Y: Suppression of lactate dehydrogenase A compromises tumor progression by downregulation of the Warburg effect in glioblastoma. Neuroreport 27: 110-115, 2016.
13. Özcan E and Çakir T: Reconstructed metabolic network models predict flux-level metabolic reprogramming in glioblastoma. Front Neurosci 10: 156, 2016.
14. Wu J, Liu Y, Cho K, Dong X, Teng L, Han D, Liu H, Chen X, Chen X, Hou X, et al: Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming. Neuroreport 27: 136-144, 2016.
15. Yuen CA, Asuthkar S, Guda MR, Tsung AJ and Velpula KK: Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: A new target gleaned from an old concept. CNS Oncol 5: 101-108, 2016.
16. Jiang W, Finniss S, Cazacu S, Xiang C, Brodie Z, Mikkelsen T, Poisson L, Shackelford DB and Brodie C: Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget: Jul 29, 2016 (Epub ahead of print). doi: 10.18632/oncotarget.10919.
17. Shen H, Hau E, Joshi S, Dilda PJ and McDonald KL: Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism. Mol Cancer Ther 14: 1794-1804, 2015.
18. Yang W, Wei J, Guo T, Shen Y and Liu F: Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp Cell Res 326: 22-35, 2014.
19. Agrawal R, Pandey P, Jha P, Dwivedi V, Sarkar C and Kulshreshtha R: Hypoxic signature of microRNAs in glioblastoma: Insights from small RNA deep sequencing. BMC Genomics 15: 686, 2014.
20. Velpula KK, Bhasin A, Asuthkar S and Tsung AJ: Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res 73: 7277-7289, 2013.
21. Nie Q, Guo P, Guo L, Lan J, Lin Y, Guo F, Zhou S, Ge J, Mao Q, Li X, et al: Overexpression of isocitrate dehydrogenase-1R132H enhances the proliferation of A172 glioma cells via aerobic glycolysis. Mol Med Rep 11: 3715-3721, 2015.
22. Inukai M, Hara A, Yasui Y, Kumabe T, Matsumoto T and Saegusa M: Hypoxia-mediated cancer stem cells in pseudopalisades with activation of hypoxia-inducible factor-1α/Akt axis in glioblastoma. Hum Pathol 46: 1496-1505, 2015.
23. Xu G, Wang M, Xie W and Bai X: Hypoxia-inducible factor-1 alpha C1772T gene polymorphism and glioma risk: A hospital-based case-control study from China. Genet Test Mol Biomarkers 15: 461-464, 2011.
24. Adams DJ, Waud WR, Wani MC, Manikumar G, Flowers JL, Driscoll TA and Morgan LR: BACPTDP: A water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. Cancer Chemother Pharmacol 67: 855-865, 2011.
25. Florczyk SJ, Wang K, Jana S, Wood DL, Sytsma SK, Sham JG, Kievit FM and Zhang M: Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. Biomaterials 34: 10143-10150, 2013.
26. Maroni P, Matteucci E, Drago L, Banfi G, Bendinelli P and Desiderio MA: Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma. Exp Cell Res 330: 287-299, 2015.
27. Lv L, Yuan J, Huang T, Zhang C, Zhu Z, Wang L, Jiang G and Zeng F: Stabilization of Snail by HIF-1α and TNF-α is required for hypoxia-induced invasion in prostate cancer PC3 cells. Mol Biol Rep 41: 4573-4582, 2014.
28. Mashiko R, Takano S, Ishikawa E, Yamamoto T, Nakai K and Matsumura A: Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 102: 43-50, 2011.
29. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rössler K, et al: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes. Brain Pathol 13: 133-143, 2003.
30. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY and Jensen RL: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 113: 1032-1042, 2008.
31. Yuan G, Yan SF, Xue H, Zhang P, Sun JT and Li G: Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem 289: 10607-10619, 2014.
32. Yang YT, Ju TC and Yang DI: Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J Neurochem 93: 513-525, 2005.
33. Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, Zhao L, Chen FH, Wang XT, You QD, et al: HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 19: 284-294, 2012.
34. Gammoh N, Fraser J, Puente C, Syred HM, Kang H, Ozawa T, Lam D, Acosta JC, Finch AJ, Holland E, et al: Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy 12: 1431-1439, 2016.
35. Maugeri G, Grazia D'Amico A, Reitano R, Magro G, Cavallaro S, Salomone S and D'Agata V: PACAP and VIP inhibit the invasiveness of glioblastoma cells exposed to hypoxia through the regulation of HIFs and EGFR expression. Front Pharmacol 7: 139, 2016.
36. Li J, Ke Y, Huang M, Huang S and Liang Y: Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry of hypoxic human glioma cells. Exp Ther Med 9: 977-981, 2015.
37. Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, Maxwell R and Stoll EA: Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol: Jun 29, 2016 (Epub ahead of print). pii: now128.
38. Han D, Wei W, Chen X, Zhang Y, Wang Y, Zhang J, Wang X, Yu T, Hu Q, Liu N, et al: NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells. Oncotarget 6: 26119-26128, 2015.
39. Womeldorff M, Gillespie D and Jensen RL: Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. Neurosurg Focus 37: E8, 2014.
40. Xie Q, Bao X, Chen ZH, Xu Y, Keep RF, Muraszko KM, Xi G and Hua Y: Role of protease-activated receptor-1 in glioma growth. Acta Neurochir (Suppl 121): S355-S360, 2016.
41. Ahmad F, Dixit D, Joshi SD and Sen E: G9a inhibition induced PKM2 regulates autophagic responses. Int J Biochem Cell Biol 78: 87-95, 2016.
42. Okamoto K, Ito D, Miyazaki K, Watanabe S, Tohyama O, Yokoi A, Ozawa Y, Asano M, Kawamura T, Yamane Y, et al: Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor. Int J Mol Med 29: 541-549, 2012.
43. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W and Heimberger AB: Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6: e16195, 2011.
44. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, Mörgelin M, Bourseau-Guilmain E, Bengzon J and Belting M: Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 110: 7312-7317, 2013.
45. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD and Maity A: Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471-479, 2006.
46. Joshi S, Singh AR and Durden DL: MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem 289: 22785-22797, 2014.
47. Muh CR, Joshi S, Singh AR, Kesari S, Durden DL and Makale MT: PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: Role of HIF1α suppression. J Neurooncol 116: 89-97, 2014.
48. Hsu CC, Wang CH, Wu LC, Hsia CY, Chi CW, Yin PH, Chang CJ, Sung MT, Wei YH, Lu SH, et al: Mitochondrial dysfunction represses HIF-1α protein synthesis through AMPK activation in human hepatoma HepG2 cells. Biochim Biophys Acta 1830: 4743-4751, 2013.
49. Chae YC, Vaira V, Caino MC, Tang HY, Seo JH, Kossenkov AV, Ottobrini L, Martelli C, Lucignani G, Bertolini I, et al: Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell 30: 257-272, 2016.
50. Razorenova OV, Castellini L, Colavitti R, Edgington LE, Nicolau M, Huang X, Bedogni B, Mills EM, Bogyo M and Giaccia AJ: The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Mol Cell Biol 34: 739-751, 2014.
51. Lo Dico A, Martelli C, Valtorta S, Raccagni I, Diceglie C, Belloli S, Gianelli U, Vaira V, Politi LS, Bosari S, et al: Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. Eur J Nucl Med Mol Imaging 42: 1093-1105, 2015.
52. Madan E, Dikshit B, Gowda SH, Srivastava C, Sarkar C, Chattopadhyay P, Sinha S and Chosdol K: FAT1 is a novel upstream regulator of HIF1α and invasion of high grade glioma. Int J Cancer 139: 2570-2582, 2016.
53. Minchenko OH, Kharkova AP, Minchenko DO and Karbovskyi LL: Effect of hypoxia on the expression of genes that encode some IGFBP and CCN proteins in U87 glioma cells depends on IRE1 signaling. Ukr Biochem J 87: 52-63, 2015.
54. Hu J and Wang XF: HIF-miR-215-KDM1B promotes gliomainitiating cell adaptation to hypoxia. Cell Cycle 15: 1939-1940, 2016.
55. Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, et al: MiR-215 is induced post-transcriptionally via HIF-Drosha complex and mediates glioma-initiating cell adaptation to hypoxia by targeting KDM1B. Cancer Cell 29: 49-60, 2016.
56. Lan J, Xue Y, Chen H, Zhao S, Wu Z, Fang J, Han C and Lou M: Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett 588: 3333-3339, 2014.
57. Xue H, Guo X, Han X, Yan S, Zhang J, Xu S, Li T, Guo X, Zhang P, Gao X, et al: MicroRNA-584-3p, a novel tumor suppressor and prognostic marker, reduces the migration and invasion of human glioma cells by targeting hypoxia-induced ROCK1. Oncotarget 7: 4785-4805, 2016.
58. Jensen RL: Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92: 317-335, 2009.
59. Tivnan A and McDonald KL: Current progress for the use of miRNAs in glioblastoma treatment. Mol Neurobiol 48: 757-768, 2013.
60. Kalkan R: Hypoxia is the driving force behind GBM and could be a new tool in GBM treatment. Crit Rev Eukaryot Gene Expr 25: 363-369, 2015.
61. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
62. Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
63. Ruan K, Song G and Ouyang G: Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107: 1053-1062, 2009.
64. Oliver L, Olivier C, Marhuenda FB, Campone M and Vallette FM: Hypoxia and the malignant glioma microenvironment: Regulation and implications for therapy. Curr Mol Pharmacol 2: 263-284, 2009.
65. Tang JH, Ma ZX, Huang GH, Xu QF, Xiang Y, Li N, Sidlauskas K, Zhang EE and Lv SQ: Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. Exp Cell Res 343: 148-158, 2016.
66. Chen W, Xiao Z, Zhao Y, Huang L and Du G: HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep 30: 2495-2501, 2013.
67. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004.
68. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J and Schulz JB: Hypoxic neuroprotection requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22: 6401-6407, 2002.
69. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH and Acker T: Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 70: 357-366, 2010.
70. Mancini M, Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Pagin M and Monti E: Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer 110: 2865-2873, 2014.
71. Onnis B, Rapisarda A and Melillo G: Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13: 2780-2786, 2009.
72. Xia Y, Choi HK and Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49: 24-40, 2012.
73. Huang SW, Kao JK, Wu CY, Wang ST, Lee HC, Liang SM, Chen YJ and Shieh JJ: Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells. Oncotarget 5: 1363-1381, 2014.
74. Dai P, Akimaru H, Tanaka Y, Maekawa T, Nakafuku M and Ishii S: Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J Biol Chem 274: 8143-8152, 1999.
75. Regl G, Neill GW, Eichberger T, Kasper M, Ikram MS, Koller J, Hintner H, Quinn AG, Frischauf AM and Aberger F: Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma. Oncogene 21: 5529-5539, 2002.
76. Fedorchuk AG, Pyaskovskaya ON, Gorbik GV, Prokhorova IV, Kolesnik DL and Solyanik GI: Effectiveness of sodium dichloroacetate against glioma C6 depends on administration schedule and dosage. Exp Oncol 38: 80-83, 2016.
77. Wang H, Feng H and Zhang Y: Resveratrol inhibits hypoxia-induced glioma cell migration and invasion by the p-STAT3/miR-34a axis. Neoplasma 63: 532-539, 2016.
78. Li S, Wang J, Wei Y, Liu Y, Ding X, Dong B, Xu Y and Wang Y: Crucial role of TRPC6 in maintaining the stability of HIF-1α in glioma cells under hypoxia. J Cell Sci 128: 3317-3329, 2015.
79. Luan W, Wang Y, Chen X, Shi Y, Wang J, Zhang J, Qian J, Li R, Tao T, Wei W, et al: PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget 6: 13006-13018, 2015.
80. Wan YY, Zhang JF, Yang ZJ, Jiang LP, Wei YF, Lai QN, Wang JB, Xin HB and Han XJ: Involvement of Drp1 in hypoxia-induced migration of human glioblastoma U251 cells. Oncol 32: 619-626, 2014.
81. Adamski J, Price A, Dive C and Makin G: Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLoS One 8: e65304, 2013.
82. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD and Schofield CJ: Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 284: 26831-26838, 2009.
83. Maples KR, Green AR and Floyd RA: Nitrone-related therapeutics: Potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs 18: 1071-1084, 2004.
84. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA and Jensen RL: Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13: 2441-2448, 2007.
85. Sydserff SG, Borelli AR, Green AR and Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 135: 103-112, 2002.
86. Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD and Gupta N: A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol 96: 151-159, 2010.
87. de Souza PC, Smith N, Pody R, He T, Njoku C, Silasi-Mansat R, Lupu F, Meek B, Chen H, Dong Y, et al: OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model. Am J Nucl Med Mol Imaging 5: 363-378, 2015.
88. Bourne DW: BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed 29: 191-195, 1989.
89. Yamaoka K, Nakagawa T and Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165-175, 1978.
90. Coutinho de Souza P, Mallory S, Smith N, Saunders D, Li XN, McNall-Knapp RY, Fung KM and Towner RA: Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in orthotopic mouse xenografts. PLoS One 10: e0134276, 2015.
91. Liu D, Cao G, Cen Y, Liu T, Peng W, Sun J, Li X and Zhou H: The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway. Int Immunopharmacol 17: 237-244, 2013.
92. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK and Bührer C: Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 372: 892-897, 2008.
93. Belozerov VE and Van Meir EG: Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 16: 901-909, 2005.
94. Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4: 601-605, 2006.
95. Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12: 853-859, 2007.
96. Lee P, Murphy B, Miller R, Menon V, Banik NL, Giglio P, Lindhorst SM, Varma AK, Vandergrift WA III, Patel SJ, et al: Mechanisms and clinical significance of histone deacetylase inhibitors: Epigenetic glioblastoma therapy. Anticancer Res 35: 615-625, 2015.
97. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P and Pili R: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626-6634, 2004.
98. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
99. Moeini A, Cornellà H and Villanueva A: Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 1: 83-93, 2012.
100. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, et al: E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137: 361-371, 371.e1-371.e5, 2009.
101. Falkenberg KJ and Johnstone RW: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13: 673-691, 2014.
102. Singh MM, Johnson B, Venkatarayan A, Flores ER, Zhang J, Su X, Barton M, Lang F and Chandra J: Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol 17: 1463-1473, 2015.
103. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D and Karnitz L: An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25: 151-159, 2007.
104. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C and Rizvi S: Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2: 31, 2009.
105. Miyar A, Habibi I, Ebrahimi A, Mansourpour D, Mokarizadeh A, Rajabi A, Farshgar R, Eshaghzadeh M, Zamani-Ahmadmahmudi M and Nodushan SM: Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis. J Neurol Sci 368: 314-317, 2016.
106. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N and Newcomb EW: Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196: 394-402, 2003.
107. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S and Neri LM: The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 6: 17147-17160, 2015.
108. Huang WJ, Liang YC, Chuang SE, Chi LL, Lee CY, Lin CW, Chen AL, Huang JS, Chiu CJ, Lee CF, Huang CY and Chen CN: NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity. Evid Based Complement Alternat Med 2012: 781417, 2012.
109. Huang WJ, Lin CW, Lee CY, Chi LL, Chao YC, Wang HN, Chiou BL, Chen TJ, Huang CY and Chen CN: NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol 136: 156-167, 2011.
110. Zhang W, Lv S, Liu J, Zang Z, Yin J, An N, Yang H and Song Y: PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway. Genet Mol Biol 37: 716-724, 2014.
111. Redjal N, Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J and Nahed BV: Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. J Neurooncol 127: 505-514, 2016.
112. Hoja S, Schulze M, Rehli M, Proescholdt M, Herold-Mende C, Hau P and Riemenschneider MJ: Molecular dissection of the valproic acid effects on glioma cells. Oncotarget: Aug 18, 2016 (Epub ahead of print). doi: 10.18632/oncotarget.11379.
113. Berghauser Pont LM, Kleijn A, Kloezeman JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven CM and Lamfers ML: The HDAC inhibitors scriptaid and LBH589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells. PLoS One 10: e0127058, 2015.
114. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE and Huang Y: Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 34: 1196-1207, 2013.
115. Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, Huang H, Tsui K, Shen J and Chen J: Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One 8: e68566, 2013.
116. Zhao S, Chang H, Ma P, Gao G, Jin C, Zhao X, Zhou W and Jin B: Inhibitory effect of DNA topoisomerase inhibitor isoliquiritigenin on the growth of glioma cells. Int J Clin Exp Pathol 8: 12577-12582, 2015.
117. Zhou GS, Song LJ and Yang B: Isoliquiritigenin inhibits proliferation and induces apoptosis of U87 human glioma cells in vitro. Mol Med Rep 7: 531-536, 2013.
118. Ma J, Han LZ, Liang H, Mi C, Shi H, Lee JJ and Jin X: Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. Oncol Rep 32: 235-242, 2014.
119. Zhou YX and Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: An in vitro and in vivo study. Chin Med J 122: 1666-1673, 2009.
120. Huang Y, Zhou Y, Fan Y and Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264: 101-106, 2008.
121. Bordji K, Grandval A, Cuhna-Alves L, Lechapt-Zalcman E and Bernaudin M: Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. FEBS J 281: 5220-5236, 2014.
122. Bache M, Rot S, Keßler J, Güttler A, Wichmann H, Greither T, Wach S, Taubert H, Söling A, Bilkenroth U, et al: mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncol Rep 33: 3155-3161, 2015.
123. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, et al: State of the science: An update on renal cell carcinoma. Mol Cancer Res 10: 859-880, 2012.
124. Bhagat M, Palanichamy JK, Ramalingam P, Mudassir M, Irshad K, Chosdol K, Sarkar C, Seth P, Goswami S, Sinha S, et al: HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis. Int J Biochem Cell Biol 74: 60-71, 2016.
125. Miranda-Gonçalves V, Granja S, Martinho O, Honavar M, Pojo M, Costa BM, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, et al: Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget: Jun 16, 2016 (Epub ahead of print). doi: 10.18632/oncotarget.
126. Zhang J, Zhu L, Fang J, Ge Z and Li X: LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation. J Exp Clin Cancer Res 35: 29, 2016.
127. Li S, Zhang J, Yang H, Wu C, Dang X and Liu Y: Copper depletion inhibits CoCl2-induced aggressive phenotype of MCF-7 cells via downregulation of HIF-1 and inhibition of Snail/Twist-mediated epithelial-mesenchymal transition. Sci Rep 5: 12410, 2015.
128. Ishii A, Kimura T, Sadahiro H, Kawano H, Takubo K, Suzuki M and Ikeda E: Histological characterization of the tumorigenic 'peri-necrotic niche' harboring quiescent stem-like tumor cells in glioblastoma. PLoS One 11: e0147366, 2016.
129. Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, et al: Activation of hypoxia signaling induces phenotypic transformation of glioma cells: Implications for bevacizumab antiangiogenic therapy. Oncotarget 6: 11882-11893, 2015.
130. Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH, Purow BW and Lee KS: Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia. PLoS One 9: e111199, 2014.
131. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R and Sterneck E: The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J 29: 4106-4117, 2010.
132. Sudhagar S, Sathya S and Lakshmi BS: Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTORdependent expression of HIF-1α in breast cancer cells. Br J Cancer 105: 953-960, 2011.